{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:13:57Z","timestamp":1795209237608,"version":"4.10.3"},"reference-count":38,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,9]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>HSCT after PD-1 blockade is feasible, although may be associated with increased early immune toxicity. PD-1 blockade may cause persistent depletion of PD1+ T cells and alterations in T-cell differentiation impacting subsequent treatment.<\/jats:p>","DOI":"10.1182\/blood-2016-09-738385","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T22:10:45Z","timestamp":1484086245000},"page":"1380-1388","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":223,"title":["Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma"],"prefix":"10.1182","volume":"129","author":[{"given":"Reid W.","family":"Merryman","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[{"name":"Humanitas Clinical & Research Center, Milan, Italy;"},{"name":"Department of Oncology and Hematology, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[{"name":"Division of Hematology and Bone-Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad S.","family":"Halwani","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, Salt Lake City, UT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire (CHU) Rennes, Service H\u00e9matologie Clinique, Rennes, France;"},{"name":"INSERM, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Marchand","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire (CHU) Rennes, Service H\u00e9matologie Clinique, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Dhedin","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Louis, Service H\u00e9matologie Adolescents et Jeunes Adultes, Assistance Publique-H\u00f4pitaux de Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Lescaut","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Princesse Grace, Service M\u00e9decine Interne et Onco-H\u00e9matologie, Monaco, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Thiebaut-Bertrand","sequence":"additional","affiliation":[{"name":"CHU Grenoble, Clinique Universitaire d\u2019H\u00e9matologie, Grenoble, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Fran\u00e7ois","sequence":"additional","affiliation":[{"name":"CHU Angers, Service Maladies du Sang, Angers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Stamatoullas-Bastard","sequence":"additional","affiliation":[{"name":"Centre Henri Becquerel, Service H\u00e9matologie Clinique, Rouen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Simon","family":"Rohrlich","sequence":"additional","affiliation":[{"name":"CHU Nice, Service H\u00e9matologie et Onco-H\u00e9matologie P\u00e9diatrique, Nice, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re Wallet","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, Service d'H\u00e9matologie Clinique, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[{"name":"Humanitas Clinical & Research Center, Milan, Italy;"},{"name":"Department of Oncology and Hematology, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Humanitas Clinical & Research Center, Milan, Italy;"},{"name":"Department of Oncology and Hematology, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Bresler","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabh","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harim","family":"Kim","sequence":"additional","affiliation":[{"name":"University College of Medicine, Seoul National University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Pesek","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Chammas","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019111902591031000_B1","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111902591031000_B2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"4","key":"2019111902591031000_B3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2019111902591031000_B4","first-page":"JCO673467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure [published online ahead of print 27 June 2016]","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"2019111902591031000_B5","first-page":"1","article-title":"Highlights of Prescribing Information - Nivolumab","volume-title":"US Food Drug Adm","year":"2014"},{"issue":"23","key":"2019111902591031000_B6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.V126.23.834.834","article-title":"PD-1 blockade with pembrolizumab (MK-3475) in relapsed\/refractory CLL including richter transformation: an early efficacy report from a phase 2 trial (MC1485) [abstract]","volume":"126","author":"Ding","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111902591031000_B7","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111902591031000_B8","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Hoos","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2019111902591031000_B9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.immuni.2015.12.008","article-title":"The PD-1 axis enforces an anatomical segregation of CTL activity that creates tumor niches after allogeneic hematopoietic stem cell transplantation","volume":"44","author":"Michonneau","year":"2016","journal-title":"Immunity"},{"issue":"17","key":"2019111902591031000_B10","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111902591031000_B11","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","article-title":"Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism","volume":"171","author":"Blazar","year":"2003","journal-title":"J Immunol"},{"issue":"23","key":"2019111902591031000_B12","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/blood.V126.23.3979.3979","article-title":"Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin\u2019s lymphoma after allogeneic hematopoietic cell transplantation: a study from the Lysa and SFGM-TC [abstract]","volume":"126","author":"Herbaux","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111902591031000_B13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111902591031000_B14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood"},{"key":"2019111902591031000_B15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"9","key":"2019111902591031000_B16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.bmt.1703015","article-title":"Engraftment syndrome following hematopoietic stem cell transplantation","volume":"27","author":"Spitzer","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019111902591031000_B17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.bmt.1703855","article-title":"Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria","volume":"31","author":"Maiolino","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2019111902591031000_B18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111902591031000_B19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica"},{"issue":"11","key":"2019111902591031000_B20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","article-title":"The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade","volume":"17","author":"Carreras","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2019111902591031000_B21","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111902591031000_B22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13931","article-title":"The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111902591031000_B23","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111902591031000_B24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2019111902591031000_B25","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research Analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111902591031000_B26","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111902591031000_B27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study\u2014a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"2019111902591031000_B28","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.bbmt.2016.03.028","article-title":"Gemcitabine, fludarabine, and melphalan for reduced-intensity conditioning and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"22","author":"Anderlini","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111902591031000_B29","first-page":"8892","article-title":"Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro","volume":"8","author":"Pang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"2019111902591031000_B30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bmt.2012.232","article-title":"Frequency of CD4(+)FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD","volume":"48","author":"Fujioka","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"111","key":"2019111902591031000_B31","doi-asserted-by":"crossref","first-page":"111ra120","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci Transl Med"},{"issue":"23","key":"2019111902591031000_B32","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V126.23.848.848","article-title":"PD-1 signaling has a critical role in maintaining regulatory T cell homeostasis; implication for Treg depletion therapy by PD-1 blockade [abstract]","volume":"126","author":"Asano","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111902591031000_B33","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.4049\/jimmunol.175.11.7372","article-title":"Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes","volume":"175","author":"Keir","year":"2005","journal-title":"J Immunol"},{"issue":"3-4","key":"2019111902591031000_B34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaut.2011.02.009","article-title":"Programmed death-1 is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasis","volume":"36","author":"Thangavelu","year":"2011","journal-title":"J Autoimmun"},{"issue":"9","key":"2019111902591031000_B35","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.4049\/jimmunol.171.9.4574","article-title":"Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4\/CD8 double-negative TCR-transgenic T cells","volume":"171","author":"Blank","year":"2003","journal-title":"J Immunol"},{"issue":"2","key":"2019111902591031000_B36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1084\/jem.20121458","article-title":"Helios marks strongly autoreactive CD4+ T cells in two major waves of thymic deletion distinguished by induction of PD-1 or NF-\u03baB","volume":"210","author":"Daley","year":"2013","journal-title":"J Exp Med"},{"key":"2019111902591031000_B37","first-page":"1","article-title":"Highlights of Prescribing Information - Pembrolizumab","volume-title":"US Food Drug Adm","year":"2014"},{"issue":"12","key":"2019111902591031000_B38","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.bbmt.2007.08.006","article-title":"Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival","volume":"13","author":"Eapen","year":"2007","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/10\/1380\/1398753\/blood738385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/10\/1380\/1398753\/blood738385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:59:57Z","timestamp":1574132397000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/10\/1380\/35994\/Safety-and-efficacy-of-allogeneic-hematopoietic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,3,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-09-738385","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727498791.793530715","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}